According to the data, 109 antibiotics are currently in the development pipeline, approximately 70 percent of which are in early development (preclinical and phase 1). In contrast, there are 31 at phase 2 and just 9 candidates at phase 3. Despite concerns over antibiotic-resistant pathogens, the data suggests the emergence of new types of antibiotics and strategies that will be available to target pathogens in the future.
Related Articles on Antibiotics:
4 Prognostic Variables Determined to be Risk Factors for MRSA
Varying Antibiotics Equally Effective in Treating Clostridium Difficile Infections
Providers Often Overtreat Enterococcal Bacteria With Antibiotics
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
